

Special Issue

Vaccine Against Sexually Transmitted Diseases

Message from the Guest Editor

This Special Issue, entitled "Vaccine Against Sexually Transmitted Diseases", of *Vaccines* highlights cutting-edge research and innovative strategies aimed at combating sexually transmitted infections (STIs) through vaccination. It features breakthroughs in vaccine development, targeting prevalent STIs such as human papillomavirus (HPV), HIV, syphilis, gonorrhea, and chlamydia. This Special Issue emphasizes the importance of preventive measures, equitable access to vaccines, and the integration of vaccination programs into public health initiatives. By showcasing interdisciplinary collaborations and emerging technologies, this Special Issue aims to foster dialogue among researchers, clinicians, and policymakers to enhance global health outcomes and reduce the burden of STIs.

Guest Editor

Dr. Weiming Tang

1. Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
2. Institute for Global Health and Sexually Transmitted Diseases, Southern Medical University, Guangzhou 510315, China

Deadline for manuscript submissions

30 September 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/217877

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).